DRUG
C1 Inhibitor Human
standard care + 1000 units of C1 inhibitor during 2 slow infusions of 500 units
Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).
Status
Completed
Phase
Phase 2
Enrollment
44
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The main objective of this study is to evaluate the efficacy of human C1 inhibitor, administered alone or in combination with icatibant (a specific bradykinin B2 receptor antagonist) on the pulmonary manifestations of COVID-19 infections.
Full detailed description
Prospective, prospective, multicentre, double-blind, randomised, multi-centre study of three parallel groups of patients: * Group 1 (n=15): standard of care + C1 inhibitor * Group 2 (n=15): standard care + icatibant + C1 inhibitor * Group 3 (n=15): standard support + placebo The study has two parts: * A 4-day (96-hour) therapeutic part during which the patient will be evaluated nine times (H0, H4, H12, H24, H36, H48, H60, H72 and H96). * A follow-up part of 6 days with at least two assessments (D7 and D10). The maximum duration of patient participation in the study will be 10 days.
Interventions
Treatment arms and agents.
DRUG
Icatibant Injection
a single injection of 30 mg subcutaneously
OTHER
Placebo
The placebo will be physiological serum presented in forms mimicking the C1-Inhibitor and the icatibant.
Timeline
From registration to results.
First posted
Aug 18, 2021
Study start
Feb 4, 2021
Primary completion
Jun 13, 2021
Study completion
Jun 21, 2021
Results posted
Not reported
Registry updated
Dec 22, 2022
Outcomes
What the study measures.
Primary outcomes
Efficacy evaluation respiratory discomfort
Time frame · 96 hours after the administration of treatment
To evaluate the efficacy of human C1 inhibitor, administered alone or in combination with icatibant (a specific bradykinin B2 receptor antagonist) on the pulmonary manifestations of COVID-19 infections. The evaluation of the treatment efficacy of the study is based on the clinical monitoring of the patient and particularly on the following combination of criteria as experienced by the patient : * no respiratory discomfort * heart rate between 60 and 90 /min * respiratory rate less than 20/min * O2 saturation greater than 94% without oxygen supply
Efficacy evaluation heart rate between 60 and 90 /min
Time frame · 96 hours after the administration of treatment
To evaluate the efficacy of human C1 inhibitor, administered alone or in combination with icatibant (a specific bradykinin B2 receptor antagonist) on the pulmonary manifestations of COVID-19 infections. The evaluation of the treatment efficacy of the study is based on the clinical monitoring of the patient and particularly on the following combination of criteria as experienced by the patient : * no respiratory discomfort * heart rate between 60 and 90 /min * respiratory rate less than 20/min * O2 saturation greater than 94% without oxygen supply
Efficacy evaluation respiratory rate less than 20/min
Time frame · 96 hours after the administration of treatment
To evaluate the efficacy of human C1 inhibitor, administered alone or in combination with icatibant (a specific bradykinin B2 receptor antagonist) on the pulmonary manifestations of COVID-19 infections. The evaluation of the treatment efficacy of the study is based on the clinical monitoring of the patient and particularly on the following combination of criteria as experienced by the patient : * no respiratory discomfort * heart rate between 60 and 90 /min * respiratory rate less than 20/min * O2 saturation greater than 94% without oxygen supply
Efficacy evaluation O2 saturation greater than 94% without oxygen supply
Time frame · 96 hours after the administration of treatment
To evaluate the efficacy of human C1 inhibitor, administered alone or in combination with icatibant (a specific bradykinin B2 receptor antagonist) on the pulmonary manifestations of COVID-19 infections. The evaluation of the treatment efficacy of the study is based on the clinical monitoring of the patient and particularly on the following combination of criteria as experienced by the patient : * no respiratory discomfort * heart rate between 60 and 90 /min * respiratory rate less than 20/min * O2 saturation greater than 94% without oxygen supply
Secondary outcomes
Tolerance evaluation
Time frame · Day 10
The tolerance of the study products will be assessed by collecting adverse events that occurred during the study period.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Patient over 18 years of age, having read and signed the consent form for participation in the study after the reflection period (≤ 15 minutes) * Patient screened for COVID+ by RT-PCR on nasopharyngeal swab * Patient with at least three of the following respiratory signs: * Temperature \>38° C * Non-productive dry cough * Presence of crackling rales on auscultation * Respiratory discomfort felt by the patient * Heart rate \> 90/min * Respiratory rate \>20/min * O2 saturation ≤ 93% * Patient whose clinical condition, in the opinion of the investigator, requires hospital monitoring. * Patient who would have been monitored and treated outside of study participation, including prevention of thromboembolic risk with LMWH. Exclusion Criteria: * Patient with pre-existing respiratory disease (cancer, COPD, asthma, emphysema) or smoking history of \> 25 years) * Patient with a known allergy to one of the study products * Patient treated with anti TNF, IL1 or IL6 * Patient requiring immediate intubation * Patient on a low sodium diet * Patient under protective custody, guardianship or trusteeship * Patient not affiliated to the French social security system * Patient participating in another therapeutic protocol * Pregnant or likely to become pregnant (woman of childbearing age without effective contraception and without HCG dosage) * Patient unable to understand informed information and/or give written informed consent: dementia, psychosis, consciousness disorders, non-French speaking patient
Study locations
1 registered sites.
France. Showing up to 24 locations stored in the fast local snapshot.
Hôpital Privé de Parly II
Le Chesnay, France
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Icatibant.
NCT IDStudyPhase / statusEnrollmentUpdated
A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema
Takeda · Hereditary Angioedema (HAE)
Not applicable
Completed
32
2026-07
Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor
Vanderbilt University Medical Center · Intradialytic Hypotension
Phase 3
Recruiting
26
2026-04
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
QuantumLeap Healthcare Collaborative · COVID-19
Phase 2
Active, not recruiting
1,500
2026-03
A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China
Takeda · Hereditary Angioedema (HAE)
Not applicable
Completed
115
2026-01
A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks
KalVista Pharmaceuticals, Ltd. · Hereditary Angioedema
Not applicable
Completed
88
2026-01
A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema
Nang Kuang Pharmaceutical Co., Ltd. · Bradykinin-mediated Angioedema · Hereditary Angioedema (HAE)
Phase 4
Completed
5
2025-12
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2
Vanderbilt University Medical Center · Heart Failure
Phase 4
Completed
46
2025-08
FIRAZYR General Drug Use-Results Survey (Japan)
Shire · Hereditary Angioedema (HAE)
Not applicable
Completed
179
2025-02
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.